Betibeglogene Autotemcel

Definition

A preparation of autologous, CD34-positive hematopoietic stem cells (HSCs) transduced ex vivo with the BB305 recombinant replication-defective, self-inactivating lentiviral vector encoding for an engineered form of human beta-globin (hemoglobin-beta, HBB) gene, beta-A-T87Q (b-A-T87Q) where the threonine at position 87 has been substituted with glutamine, with potential to restore beta-globin expression and function. Autologous CD34-positive stem cells are isolated from the patient's own bone marrow and the cells are transduced with the lentiviral vector. Upon re-infusion of betibeglogene autotemcel back into the patient, these cells express b-A-T87Q-globin, thereby allowing the body to make normal hemoglobin and thus normal, healthy red blood cells. Beta-globin, the beta-chain of the most common form of hemoglobin, is encoded by the HBB gene; mutations in this gene prevent normal beta-globin production and are associated with beta-thalassemia and sickle cell anemia. The b-A-T87Q form of beta-globin has increased antisickling activity compared to the wild type protein.

Also known as Autologous CD34+ Cells Encoding beta-A-T87Q-globin Gene, Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo with Betibeglogene Darolentivec, Autologous CD34+ HSCs Transduced with LentiGlobin BB305, BETIBEGLOGENE AUTOTEMCEL, LentiGlobin BB305 Drug Product for TDT, LentiGlobin BB305 Lentiviral Vector-transduced Autologous CD34+ HSCs, LentiGlobin BB305-transduced CD34-positive Cells, LentiGlobin Drug Product for Transfusion Dependent beta-Thalassemia, Lentiviral b-A(T87Q)-Globin-transduced CD34-positive Cells, Zynteglo — per NCIT

Also identified as

• ATC B06AX02 per RXNORM
• NCIT NCIT:C123881 per NCIT
• UNII MEE8487RTP per RXNORM

Indications